Outgoing CEO Kevin Sayer expects expanding coverage of Dexcom’s glucose sensors for people with Type 2 diabetes and ...

Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 15.2% year on ...

DexCom, Inc . DXCM reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, which beat the Zacks Consensus ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

The recall affects Dexcom G6, G7, ONE, and ONE+ continuous glucose monitor receivers but not the smartphone apps or insulin ...

Innovations are expanding the number of people who can benefit from continuous glucose monitoring and a recent move by ...

DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging ...

SAN DIEGO - Dexcom reported revenue growth of 15% year-over-year to $1.157 billion for the second quarter of 2025.

DexCom reports 15% Q2 2025 revenue growth, boosted by expanded type 2 diabetes access & product innovation. Discover their raised outlook & future plans.

Dexcom's growth in sensors and U.S. expansion is solid, but slowing revenue growth and high valuation limit upside. Click ...

Dexcom is recalling 19 models of its continuous glucose monitoring receivers due to a speaker malfunction that could prevent alerts for dangerous blood sugar levels. The affected devices are models ...